HTF Market Intelligence released a new research report of 167 pages on title Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2017 with detailed analysis, forecast and strategies. The study covers key regions that includes North America, Europe and Asia-Pacific, South America, Middle East and Africa and important players such as Aevi Genomic Medicine Inc 29
Request a sample report @ https://www.htfmarketreport.com/sample-report/291952-attention-deficit-hyperactivity-disorder-1
Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2017
latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder – Pipeline Review, H1 2017, provides an overview of the Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline landscape.
Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.
Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 6, 11, 8, 15, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.
Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/291952-attention-deficit-hyperactivity-disorder-1
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Attention Deficit Hyperactivity Disorder (ADHD) – Overview 8
Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Attention Deficit Hyperactivity Disorder (ADHD) – Companies Involved in Therapeutics Development 29
Aevi Genomic Medicine Inc 29
Alcobra Ltd 29
Amarantus Bioscience Holdings Inc 30
APeT Holding BV 30
Arbor Pharmaceuticals LLC 31
BCWorld Pharm Co Ltd 31
BioHealthonomics Inc 32
BioLite Inc 32
Cingulate Therapeutics LLC 33
Collegium Pharmaceutical Inc 33
Curemark LLC 34
DURECT Corp 34
Eli Lilly and Company 35
Ensysce Biosciences Inc 35
H. Lundbeck A/S 36
Heptares Therapeutics Ltd 36
Highland Therapeutics Inc 37
Integrative Research Laboratories Sweden AB 37
INVENT Pharmaceuticals Inc 38
KemPharm Inc 38
Luc Therapeutics Inc 39
Merck & Co Inc 39
Neos Therapeutics Inc 40
NeuroDerm Ltd 40
Neurovance Inc 41
NLS Pharma Group 41
Noven Pharmaceuticals Inc 42
P2D Bioscience 42
Reviva Pharmaceuticals Inc 43
Shire Plc 43
SK Biopharmaceuticals Co Ltd 44
Sunovion Pharmaceuticals Inc 44
Supernus Pharmaceuticals Inc 45
Taisho Pharmaceutical Co Ltd 45
TRImaran Pharma Inc 46
Attention Deficit Hyperactivity Disorder (ADHD) – Drug Profiles 47
(nicotine + opipramol hydrochloride) – Drug Profile 47
4-P003 – Drug Profile 48
AR-08 – Drug Profile 49
BCWPE-003 – Drug Profile 50
BLI-1008 – Drug Profile 51
BNC-375 – Drug Profile 52
CB-8411 – Drug Profile 54
centanafadine SR – Drug Profile 55
CM-4612 – Drug Profile 58
CTX-1301 – Drug Profile 59
CTX-1302 – Drug Profile 60
dasotraline hydrochloride – Drug Profile 61
dextroamphetamine – Drug Profile 64
dextroamphetamine IR – Drug Profile 65
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/291952-attention-deficit-hyperactivity-disorder-1
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=291952
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218